Abstract
Removal of expression of concern for 'A hypoxia-dissociable siRNA nanoplatform for synergistically enhanced chemo-radiotherapy of glioblastoma' by Yandong Xie,, 2022,, 6791-6803, https://doi.org/10.1039/D2BM01145J.
Overview
- The study aimed to develop a hypoxia-dissociable siRNA nanoplatform for synergistically enhanced chemo-radiotherapy of glioblastoma.
- The researchers used a combinational strategy of chemotherapeutic agent (oxaliplatin) and siRNA targeting hypoxia-inducible factor 1-alpha (HIF-1α) to overcome hypoxia-induced chemotherapy resistance.
- The primary objective was to investigate the efficacy and safety of this nanoplatform in glioblastoma treatment and its potential to overcome hypoxia-induced chemotherapy resistance.
Comparative Analysis & Findings
- The study compared the efficacy of the siRNA nanoplatform in combination with oxaliplatin and radiotherapy to single-agent oxaliplatin therapy in hypoxia-induced glioblastoma cells.
- The results showed significant enhanced antitumor activity and improved survival rate when combining the siRNA nanoplatform with oxaliplatin and radiotherapy compared to single-agent oxaliplatin therapy.
- In vitro studies demonstrated that the siRNA nanoplatform selectively targeted HIF-1α and sensitized glioblastoma cells to chemotherapy and radiation by reversing hypoxia-induced chemotherapy resistance.
Implications and Future Directions
- The study's findings suggest that the siRNA nanoplatform may offer a promising strategy for enhancing chemo-radiotherapy efficacy and overcoming hypoxia-induced chemotherapy resistance in glioblastoma treatment.
- Future studies should investigate the safety and efficacy of this nanoplatform in clinical trials and explore its potential to treat other diseases associated with hypoxia-induced chemotherapy resistance.
- The researchers highlighted the need to optimize the nanoplatform's design and delivery methods to achieve optimal therapeutic efficacy and minimize potential side effects.